Gastrointestinal mucositis

Summary

Gastrointestinal mucositis (MONDO:0000888) is a disease and 3 clinical trials. Top therapeutic interventions include palifermin and amimestrocel. A subtype of digestive system disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastrointestinal mucositis
Mondo ID	MONDO:0000888
DOID	DOID:0080178
NCIT	C3853
SNOMED CT	95518006
UMLS	C0521585
MedGen	636691
Is cancer (heuristic)	no

Also known as: gastrointestinal system mucosa inflammation · gastrointestinal system mucosaitis · inflammation of gastrointestinal system mucosa

Disease family

This is a subtype of digestive system disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › gastrointestinal mucositis

Related subtypes (30): benign digestive system neoplasm, autoimmune disorder of gastrointestinal tract, diarrheal disease, pancreas disorder, hepatobiliary disorder, digestive system cancer, peptic ulcer disease, stomach disorder, intestinal disorder, Meckel diverticulum, Cronkhite-Canada syndrome, diverticulosis, small-intestinal, diverticulosis of bowel, hernia, and retinal detachment, congenital enteropathy due to enteropeptidase deficiency, hereditary mixed polyposis syndrome, caudal duplication, Moyamoya disease with early-onset achalasia, hyperplastic polyposis syndrome, thoraco-abdominal enteric duplication, digestive duplication, juvenile polyposis syndrome, umbilical cord ulceration-intestinal atresia syndrome, growth retardation-mild developmental delay-chronic hepatitis syndrome, common mesentery, neoplasm of oropharynx, gastrointestinal polyp, digestive system neuroendocrine neoplasm, digestive system infectious disorder, upper digestive tract disorder, congenital peritoneal encapsulation

Subtypes (2): inflammatory diarrhea, intestinal infectious disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07400328	PHASE2	RECRUITING	Amimestrocel Injection for Preventing Severe Oral Mucositis in HSCT Patients
NCT00728585	PHASE2	WITHDRAWN	Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant
NCT00336609	Not specified	UNKNOWN	TRIAD Burden of Illness Mucositis Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PALIFERMIN	4	1
AMIMESTROCEL	2	1